Abstract
Type 1 diabetes mellitus is a disorder of glucose regulation characterized by autoimmune destruction of the insulin-producing pancreatic β-cells and the need for lifelong insulin replacement therapy. Both glucose and HbA1c criteria are available for the diagnosis of diabetes. Achieving and maintaining near-normal blood glucose concentrations with appropriate administration of insulin is critical for successful long-term care of patients with diabetes mellitus and prevention of diabetic complications, but it is very difficult to achieve. Efforts to intensify therapy usually result in hypoglycemia. Point-of-care blood glucose testing provides the information needed by patients for clinical decision-making. Despite the ease of use and rapid reporting of modern point-of-care glucose monitoring devices, they provide measurements only intermittently. Continuous glucose monitoring devices can provide new glucose measurements every 5 minutes and may facilitate better glucose control. The development of new technologies that integrate continuous glucose monitoring technology with insulin pumps and a control algorithm to create a system for automated insulin delivery has the potential to significantly improve glycemic control, reduce hypoglycemia, and reduce the burden of care in type 1 diabetes mellitus.
Original language | English |
---|---|
Pages (from-to) | 37-40 |
Number of pages | 4 |
Journal | Point of Care |
Volume | 16 |
Issue number | 1 |
DOIs | |
State | Published - 1 Mar 2017 |
Keywords
- C-peptide
- Continuous glucose monitoring
- Hemoglobin A1c
- Insulin
- Point-of-care
- Self-monitoring blood glucose
- Type 1 diabetes
ASJC Scopus subject areas
- General Nursing